Amgen and Amazon Web Services (AWS) join forces to leverage generative AI and machine learning to enhance drug production efficiency.
Amgen, a leading biopharmaceutical company, is ramping up its collaboration with tech giant Amazon to revolutionize the discovery and production of medicines. By expanding its partnership with Amazon Web Services (AWS), Amgen aims to harness the power of generative artificial intelligence (AI) to increase the manufacturing throughput of pharmaceuticals. This strategic move comes as Amgen prepares to launch a state-of-the-art assembly and final product packaging facility in Ohio. With the help of AWS’s cloud platform and machine learning tools, Amgen hopes to optimize operations, improve sustainability, and minimize the need for human intervention in the manufacturing process.
Leveraging AI for Enhanced Manufacturing Efficiency
Amgen’s upcoming manufacturing facility in Ohio is set to incorporate the latest digital and robotic technology, with a connected platform on AWS using Amazon SageMaker. SageMaker, a machine learning service, will facilitate the building, training, and deployment of AI models to streamline the manufacturing process. The primary goal is to reduce reliance on human operators, thereby increasing efficiency and minimizing errors. Additionally, real-time performance metrics will be collected and reported, enabling machine learning models to predict and prevent equipment failures.
A Decade-Long Collaboration
Amgen and AWS have been collaborating for the past decade, exploring the potential of generative AI and machine learning in various aspects of the drugmaker’s research and development functions. This longstanding partnership has paved the way for Amgen to leverage Amazon’s platforms to uncover AI opportunities in other areas of its operations. By harnessing the power of AI, Amgen aims to stay at the forefront of technological advancements in the biopharmaceutical industry.
AI in the Biopharma Industry
Amgen is not the only biopharmaceutical company embracing AI in an increasingly digital world. Sanofi, a major player in the industry, recently unveiled an app developed in collaboration with AI company Aily Labs. This app provides a comprehensive overview of all Sanofi activities, marking a significant step in the company’s digital transformation. Sanofi has also integrated AI across multiple teams, including research, clinical operations, and manufacturing. Similarly, Germany’s Boehringer Ingelheim has partnered with IBM to utilize an artificial intelligence model in its drug discovery efforts. This collaboration aims to identify new antibody therapeutics, showcasing the industry’s growing reliance on AI-driven solutions.
Exploring New Possibilities
Amgen’s partnership with Amazon signifies a broader trend in the biopharma industry, where companies are increasingly embracing AI to enhance their operations. By leveraging generative AI and machine learning, Amgen aims to revolutionize pharmaceutical manufacturing and drive innovation. As the industry continues to evolve, the integration of AI technologies holds promise for improving efficiency, reducing costs, and ultimately delivering better healthcare outcomes.
Amgen’s expanded partnership with Amazon Web Services demonstrates the biopharmaceutical industry’s growing reliance on AI and machine learning to optimize drug discovery and production. By incorporating generative AI into its manufacturing process, Amgen aims to increase efficiency, improve sustainability, and reduce the need for human intervention. This collaboration is part of a broader trend in the industry, with companies like Sanofi and Boehringer Ingelheim also embracing AI to enhance their operations. As the biopharma landscape continues to evolve, AI-driven solutions have the potential to revolutionize the industry and pave the way for more efficient and effective healthcare delivery.